Jose Cabassa, MD
Neurology · New York, NYNPI 1760526164
Payments from drug & device makers
Across 680 payments — averaging $33.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$11K
- Amneal Pharmaceuticals LLC$2K
- Acadia Pharmaceuticals Inc$1K
- AbbVie$1K
- Neurelis, Inc.$1K
- Kyowa Kirin, Inc.$923
- plus $6K from 31 others
What the payments were for
- Speaking & faculty fees$9,95943%
- Travel & lodging$3532%
- Food & beverage$12,54955%
- Education$1451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acorda Therapeutics, Inc | 18 | $10,609 |
| Amneal Pharmaceuticals LLC | 101 | $1,761 |
| Acadia Pharmaceuticals Inc | 88 | $1,481 |
| AbbVie(2 entities) | 64 | $1,293 |
| Neurelis, Inc. | 72 | $1,231 |
| Kyowa Kirin, Inc. | 54 | $923 |
| MDD US Operations, LLC | 41 | $728 |
| Abbott | 11 | $518 |
| Teva Pharmaceuticals USA, Inc. | 23 | $485 |
| Neurocrine Biosciences, Inc. | 20 | $475 |
| Pfizer | 29 | $409 |
| Lilly USA, LLC | 19 | $407 |
| Lundbeck LLC | 15 | $287 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $267 |
| UCB, Inc. | 10 | $235 |
| Avion Pharmaceuticals | 17 | $233 |
| Sunovion Pharmaceuticals Inc. | 12 | $191 |
| Medtronic(2 entities) | 5 | $170 |
| Ipsen Biopharmaceuticals, Inc | 8 | $139 |
| Biogen | 9 | $133 |
| Bristol Myers Squibb | 6 | $128 |
| Vertical Pharmaceuticals, LLC | 6 | $117 |
| Eisai Inc. | 5 | $100 |
| Sanofi | 5 | $89 |
| Genentech USA, Inc. | 4 | $83 |
| Boston Scientific | 1 | $80 |
| Biohaven Pharmaceuticals, Inc. | 3 | $64 |
| Corium, LLC | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Merz Pharmaceuticals, LLC | 2 | $48 |
| Johnson & Johnson | 2 | $46 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Amgen | 1 | $29 |
| Adamas Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INBRIJA$9,640
- Infinity DBS Pulse Generators$255
- Duopa$139
- RYTARY$124
- CREXONT$119
How this compares
$23,006 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 151 | $727,576 |
| BotoxOnabotulinumtoxina | 185 | $247,490 |
| NourianzIstradefylline | 88 | $170,162 |
| DysportAbobotulinumtoxina | 56 | $95,690 |
| Budesonide ErBudesonide | 19 | $69,296 |
| Nurtec OdtRimegepant Sulfate | 29 | $38,568 |
| RytaryCarbidopa/Levodopa | 107 | $35,826 |
| GlatopaGlatiramer Acetate | 13 | $25,350 |
| UbrelvyUbrogepant | 13 | $16,574 |
| BelsomraSuvorexant | 27 | $15,330 |
| Diclofenac Sodium ErDiclofenac Sodium | 133 | $10,527 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 653 | $9,531 |
| OngentysOpicapone | 11 | $6,521 |
| Gabapentin | 1,302 | $5,565 |
| Selegiline Hcl | 118 | $3,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,481 | $727,576151 claims |
| AbbVieBotox, Ubrelvy | $1,293 | $264,064198 claims |
| Kyowa Kirin, Inc.Nourianz | $923 | $170,16288 claims |
| Ipsen Biopharmaceuticals, IncDysport | $139 | $95,69056 claims |
| PfizerNurtec Odt | $409 | $38,56829 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $1,761 | $36,046120 claims |
| Neurocrine Biosciences, Inc.Ongentys | $475 | $6,52111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Sheng-Han KuoNew York$3.2M
- Stephen KriegerNew York$3.1M
- Thomas KaleyNew York$2.9M
- Aaron MillerNew York$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.